LOGOLOGOLOGOLOGO
    • About us
      • What we do
      • Who we are
        • Governance
        • Staff
        • Vacancies
    • Members
      • EuropaBio Members
      • About Membership
    • How we work
      • Healthcare Biotechnology Council
        • Patient BioForum
        • Study – Impact of the EU’s General Pharmaceutical Legislation
      • Industrial Biotechnology Council
        • EFIB
        • Microorganisms
      • National Associations Council
      • SME Platform
      • Biomanufacturing Platform
        • Biotechnology in our Lives
    • Activities
      • 25 Years of Innovation
      • The EU Biotech Act
      • European Biotech Week
      • EU Projects
        • PRIMED Project
        • APROVALS Project
    • News & Events
      • News
      • Events
    • Library
    Become a member
    ✕

    European Commission proposal on New Genomic Techniques – a first step towards modernizing the EU GMO framework

    14/09/2023

    POSITION PAPER

    Brussels, 8 September 2023

    The European Commission’s proposal for plants produced by certain new genomic techniques (NGT legislation) is a sign of its commitment to timely and relevant policymaking to ensure food security and tackle environmental challenges such as climate change and biodiversity loss.
    The GMO framework has implications for the EU’s global competitiveness and desire for greater resiliency against climate and geopolitical dynamics. As the EU modernizes its GMO Framework, it must urgently assess and take into account scientific and technological developments in all GMO-related legislation which will inevitably be impacted.
    In this context, there are urgent scientific and economic reasons to further adapt the GMO framework for genetically modified microorganisms (GMMs). Globally, other jurisdictions are developing enabling frameworks that provide the needed regulatory certainty for industry and allow innovative products to access the market. By addressing GMMs in the GMO framework, the EU can lay out a pragmatic approach for novel products that will grow the EU’s resilience and competitiveness.

    Europe cannot afford a delay in legislation for GMMs
    Our policy asks:
    • Include in the NGT legislation a commitment for the EC to publish a proposal for additional policy actions on genetically modified microorganisms (GMMs) by 2024.
    • Accelerate the overall revision of the GMO framework across sectors beyond plants - to be in line with existing scientific advances.
    This would help increase the Union strategic autonomy by developing novel products which contribute to the resilience of agri-food systems while reducing their environmental footprint.

    European Commission proposal on New Genomic Techniques – a first step towards modernizing the EU GMO framework


    Download
    Share
    Communications Team
    Communications Team

    Related posts

    29/05/2026

    The Luxembourg Institute of Science and Technology joins EuropaBio: Advancing Applied Biotechnology in Europe


    Read more
    26/05/2026

    EuropaBio Position on the Food and Feed SafetyOmnibus (May 2026)


    Read more
    08/05/2026

    Technovative Solutions Ltd. joins EuropaBio: Advancing AI‑Driven and Sustainable Innovation in Biotechnology


    Read more

    Important links

    • The Luxembourg Institute of Science and Technology joins EuropaBio: Advancing Applied Biotechnology in Europe
    • EuropaBio Position on the Food and Feed SafetyOmnibus (May 2026)

    Categories in our Newsroom

    EBIO-white

    EuropaBio represents corporate and associate members across sectors, plus national and regional biotechnology associations which, in turn, represent over 5000 biotech companies, 4600 out of them are SMEs.

    Contact us

    Extra links

    Members
    Staff
    Privacy policy
    Legal & cookies
    Events
    Newsroom

    Become a member

    Media pack

    © 2026 Europabio. All Rights Reserved. Designed by EYAS
    Become a member

    Vitamin B2

    The biomanufacturing of Vitamin B2 led to the reduction of 75% of fossil raw materials and 50% operating costs, compared to the chemical process. Vitamin B2 is used in the food, feed or healthcare sectors.

    Insulin

    Insulin is one of the most widely known biopharmaceutical. Biotechnology revolutionised its manufacturing process and led to the development of new types of insulin through r-DNA technology.

    Detergents

    Enzymes and biosurfactancts are alternative ingredients that improve the performance of detergents, while leading to water and energy savings and reductions in CO2 emissions and water toxicity.

    Clothes

    Clothes made from alternative fibres produced by microorganisms can be 8x stronger than steel, 100% recyclable, biodegradable and replace fossil-fuel based or resource-intensive textiles.

    Algal Omega 3

    Algal Omega-3 is an innovative feed product for aquaculture. It reduces the impact on climate change by 30-40% compared to fish oil and saves 60 tons of wild fish for every ton of Algal Omega-3 used.

    Cheese

    Cheese is a vegetarian product thanks to biotechnology. Biotechnology is also essential to produce lactose- or cholesterol-free cheese, as well as alternative proteins.